LKT Labs

Biochemicals for Life Science Research

BKM120

Product ID B4248
Cas No. 944396-07-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $74.40 In stock
5 mg $206.90 In stock
Bulk Quote

Quicklinks

Description

BKM120 is an inhibitor of PI3K that is currently in clinical trials as a potential treatment for brain metastases of HER2+ breast cancer and other solid tumors. BKM120 exhibits anticancer chemotherapeutic and anti-metastatic activities, inducing G2/M phase cell cycle arrest, polyploidy, and apoptosis in glioblastoma cells. Additionally, BKM120 decreases levels of Mcl-1 and enhances TRAIL-dependent apoptosis in lung cancer cells. BKM120 also binds tubulin, inhibiting microtubule polymerization. This compound prevents invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

944396-07-0
Purity

≥98%
Formula

C18H21F3N6O2
Formula Wt.

410.39
IUPAC Name

5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
Synonym

Buparlisib, NVP-BKM120
Solubility

DMSO 82 mg/mL (199.8 mM) Ethanol 2 mg/mL (4.87 mM) Water Insoluble
Appearance

White to off white powder

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

B4248 MSDS PDF
Info Sheet

B4248 Info Sheet PDF
Brochures

PI3K-Akt-mTORC Pathway Booklet

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Wachsberger PR, Lawrence YR, Liu Y, et al. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma. J Cancer Res Clin Oncol. 2014 Feb 6. [Epub ahead of print]. PMID: 24500492.

Ando Y, Inada-Inoue M, Mitsuma A, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci. 2014 Jan 10. [Epub ahead of print]. PMID: 24405565.

Ren H, Zhao L, Li Y, et al. The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis. Cancer Lett. 2013 Sep 28;338(2):229-38. PMID: 23562472.

Brachmann SM, Kleylein-Sohn J, Gaulis S, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012 Aug;11(8):1747-57. PMID: 22653967.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.